379 results match your criteria Pathophysiology of Haemostasis and Thrombosis[Journal]


Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity.

Pathophysiol Haemost Thromb 2010 10;37(2-4):104-9. Epub 2011 May 10.

Department of Internal Medicine, Vakif Gureba Training and Research Hospital, Istanbul, Turkey.

Objective: To demonstrate the presence of splenomegaly in primary antiphospholipid syndrome (PAPS) patients without accompanying portal hypertension or comorbidity.

Methods: Twelve patients (7 women) aged 23-65 years followed upon the diagnosis of PAPS were enrolled in the study. We documented the identified causes of splenomegaly in patients with PAPS, and searched for the potential causes of splenomegaly in patients with spleen enlargement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000327506DOI Listing
October 2011
50 Reads

The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.

Pathophysiol Haemost Thromb 2010 10;37(2-4):98-103. Epub 2011 May 10.

Department of Cardiology, Center for Clinical Heart Research, Oslo University Hospital, Oslo, Norway.

In patients with stable coronary heart disease (n = 1,001) we investigated the influence of tissue factor (TF) and TF pathway inhibitor (TFPI) polymorphisms on thrombin generation in vivo, measured by prothrombin fragment (F) 1 and 2, and the potential to generate thrombin ex vivo, measured by the calibrated automated thrombogram assay. Additionally, circulating levels of TF and TFPI were correlated to the different parameters of thrombin generation. The TF 5466 and TFPI -399 polymorphisms associated with higher thrombin generation in vivo, the latter also with a prolonged lag time of the thrombin generation ex vivo(p < 0. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/327491
Publisher Site
http://dx.doi.org/10.1159/000327491DOI Listing
October 2011
8 Reads

Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.

Pathophysiol Haemost Thromb 2010 23;37(2-4):88-97. Epub 2011 Mar 23.

Department of Oncology, McMaster University, Hamilton, Ont., Canada.

Although thromboembolism is a problematic complication of chemotherapy, the pathogenic mechanisms by which chemotherapeutic agents exert prothrombotic effects in vivo are unclear.The objective of this study was to examine the effects of adjuvant chemotherapy on thrombin generation, the protein C anticoagulant pathway, and microparticle tissue factor (MP TF) activity in 26 breast cancer patients (stages I to III). The patients received cyclophosphamide, 5-fluorouracil, and methotrexate, epirubicin, or doxorubicin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000324166DOI Listing
October 2011
3 Reads

The effect of chronic cadmium toxicity on blood pressure and plasma viscosity.

Pathophysiol Haemost Thromb 2010 10;37(2-4):82-7. Epub 2011 Mar 10.

Pathophysiology Department, Faculty of Medicine, Ankara University, Ankara, Turkey.

Cadmium (Cd) is a heavy metal which affects many systems in humans and animals as a consequence of environmental and industrial pollution. The aim of this study was to investigate the effect of chronic Cd toxicity on blood pressure and plasma viscosity. Experimental group rats were given doses that contained 15 ppm CdCl(2) in drinking water for 8 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000323702DOI Listing
October 2011
3 Reads

Serum and saliva sialic acid in periodontitis patients with and without cardiovascular disease.

Pathophysiol Haemost Thromb 2010 2;37(2-4):67-71. Epub 2011 Mar 2.

Department of Basic Sciences, Faculty of Dentistry, Marmara University, Istanbul, Turkey.

Serum total sialic acid (sTSA) has recently been shown to be a cardiovascular risk factor. However, there is little information about the role of sTSA and TSA in saliva in periodontitis, a chronic and inflammatory disease known to be a risk factor for cardiovascular disease (CVD). We aimed to investigate the changes in sTSA and TSA levels in saliva in patients having both periodontitis and CVD versus periodontitis patients without diagnosed CVD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000321377DOI Listing
October 2011
8 Reads

Plasma tissue factor levels and salivary tissue factor activities of periodontitis patients with and without cardiovascular disease.

Pathophysiol Haemost Thromb 2010 4;37(2-4):77-81. Epub 2011 Feb 4.

Department of Biochemistry, Faculty of Dentistry, Marmara University, Istanbul, Turkey.

The association between periodontal and cardiovascular disease has received considerable attention. Studies have demonstrated a higher incidence of atherosclerotic complications in patients with periodontal disease. Tissue factor (TF) has been known as a key initiator of the coagulation cascade, and the TF pathway is the primary physiological mechanism of initiation of blood coagulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000323418DOI Listing
October 2011
5 Reads

Effects of short-term streptozotocin-induced diabetes and vitamin C on platelet non-enzymatic glycation.

Pathophysiol Haemost Thromb 2010 20;37(2-4):72-6. Epub 2011 Jan 20.

Medical Faculty, Istanbul Medipol University, Istanbul, Turkey.

Diabetes mellitus is one of the most prevalent metabolic syndromes worldwide. Glycation, a chemical modification of proteins with reducing sugars, indicates a possible explanation for the association between hyperglycemia and the wide variety of tissue pathologies. Non-enzymatic glycation (NEG) of platelet proteins is one of the key mechanisms in the pathogenesis of diabetic complications and may be significant in diabetic atherothrombosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000322916DOI Listing
October 2011
19 Reads

Curcumin facilitates fibrinolysis and cellular migration during wound healing by modulating urokinase plasminogen activator expression.

Pathophysiol Haemost Thromb 2010 12;37(2-4):59-66. Epub 2010 Nov 12.

Department of Applied Physiology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Urokinase plasminogen activator (uPA) plays a vital role in the early phases of wound healing by aiding fibrin dissolution and promoting the migration, proliferation, and adhesion of various cells to the wound bed. The efficacy of botanicals in healing wounds is an area of active research. Among these, curcumin, a yellow pigment abundant in turmeric rhizome, has been the center of extensive studies. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/321375
Publisher Site
http://dx.doi.org/10.1159/000321375DOI Listing
October 2011
7 Reads

An experience of oseltamivir phosphate (tamiflu™) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report.

Pathophysiol Haemost Thromb 2010 9;37(2-4):55-8. Epub 2010 Nov 9.

Department of Pediatric Hematology, Ankara Training and Research Hospital, The Ministry of Health of Turkey, Ankara, Turkey.

We report a pediatric patient with chronic idiopathic thrombocytopenic purpura who suffered from an influenza A (H1N1) virus infection. A 13-year-old girl presented with fever, coughing, and generalized petechiae. The influenza A antigen was positive in her pharyngeal aspirate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000321379DOI Listing
October 2011
6 Reads

Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience.

Pathophysiol Haemost Thromb 2010 20;37(1):30-4. Epub 2010 Oct 20.

'L & A Seragnoli' Department of Hematology and Oncological Sciences, University of Bologna, Bologna, Italy.

Venous thromboembolism (VTE) may occur during the natural history of neoplastic disease and is a common cause of mortality and morbidity in cancer patients. Major risk factors for VTE in cancer patients include surgery, immobilization, hospitalization, and the administration of granulopoietic and/or erythropoietic (stimulatory) agents. Chemotherapy is a supplementary independent risk factor for VTE and the use of central venous catheters (CVC) in clinical practice has increased the risk of thromboembolic events. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/319552
Publisher Site
http://dx.doi.org/10.1159/000319552DOI Listing
January 2011
12 Reads

New insight into the mechanism of Lonomia obliqua envenoming: toxin involvement and molecular approach.

Pathophysiol Haemost Thromb 2010 14;37(1):1-16. Epub 2010 Aug 14.

Biochemistry and Biophysics Laboratory, Butantan Institute, São Paulo, São Paulo, Brazil.

Despite the nearly worldwide distribution of Lepidoptera, there are few species with clear documentation of adverse reactions in humans. Most syndromes caused by Lepidoptera are consequences of direct contact with the hairs or setae of caterpillars. In most instances, the adverse effects caused by moth and caterpillars are self-limited and the treatment is based on the removal of hairs, application of topical antipruritics and, in some cases, the use of oral antihistamines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000320067DOI Listing
January 2011
5 Reads

Contraception-related deep venous thrombosis and pulmonary embolism in a 17-Year-old girl heterozygous for factor V leiden, prothrombin G20210A mutation, MTHFR C677T and homozygous for PAI-1 mutation: report of a family with multiple genetic risk factors and review of the literature.

Pathophysiol Haemost Thromb 2010 20;37(1):24-9. Epub 2010 Jul 20.

Departments of Laboratory Diagnostics, Children's Hospital Zagreb and University School of Medicine, Zagreb, Croatia. jasna.lenicek-krleza @ zg.htnet.hr

We present the case of a 17-year-old girl who suddenly woke up with localized pain in the left groin and the inability to twist her leg. After comprehensive physician and laboratory examinations, deep venous thrombosis with consequent pulmonary embolism was ascertained. She had not experienced any recent trauma, but she had started to take oral contraceptives 6 months prior to the onset of the symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000319051DOI Listing
January 2011
19 Reads

Levels of C-reactive protein and protein C in periodontitis patients with and without cardiovascular disease.

Pathophysiol Haemost Thromb 2010 3;37(1):49-54. Epub 2010 Jul 3.

Department of Periodontology, Faculty of Dentistry, Marmara University, Istanbul, Turkey. ezgimalali @ hotmail.com

Since periodontitis is a chronic and inflammatory disease, a number of hypotheses have proposed that it has an etiological or modulating role in cardiovascular disease (CVD). This study aimed to ascertain the changes in the plasma levels of C-reactive protein (CRP) and protein C (PC), a natural anticoagulant also having an anti-inflammatory effect, in patients who have mild-to-severe periodontitis with or without CVD. The test group consisted of 26 patients with CVD and chronic periodontitis and the control group consisted of 26 patients with chronic periodontitis and no systemic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000318189DOI Listing
January 2011
9 Reads

Platelet function and spontaneous thrombolytic activity of patients with cerebral infarction assessed by the global thrombosis test.

Pathophysiol Haemost Thromb 2010 28;37(1):43-8. Epub 2010 May 28.

Department of Neurosurgery, Ohnishi Neurological Center, Akashi, Japan. ktaomoto @ onc.akashi.hyogo.jp

Measurements of platelet reactivity and assessment of the efficacy of antiplatelet drugs are widely recognized as pre-requisite for the diagnosis and treatment of stroke patients. A recently established shear-induced platelet reactivity test using non-anticoagulated blood (the Global Thrombosis Test) has facilitated measurements of physiologically relevant platelet function and thrombolytic activity. 195 healthy volunteers, not taking antiplatelet drugs or anticoagulants, and 185 patients with acute cerebrovascular diseases were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000315494DOI Listing
January 2011
10 Reads

Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.

Pathophysiol Haemost Thromb 2010 22;37(1):17-23. Epub 2010 May 22.

Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, Calif., USA.

Coagulation factor V (FV) promotes inactivation of activated factor VIII (FVIIIa) by activated protein C (APC) and protein S. Loss of this APC cofactor activity is proposed to be partially responsible for the APC resistance phenotype of FV(Leiden). However, FVIIIa loses activity rapidly due to dissociation of the A2 domain, and this may be the primary mechanism of FVIIIa inactivation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000315141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974842PMC
January 2011
3 Reads

Platelet density distribution in essential thrombocythemia.

Pathophysiol Haemost Thromb 2010 19;37(1):35-42. Epub 2010 May 19.

Department of Internal Medicine, Vrinnevi Hospital, Norrköping, Sweden. micmi @ isv.liu.se

Essential thrombocythemia (ET) is characterized by high platelet counts and a slightly increased bleeding risk. Why severe hemorrhage does not occur more frequently is not known. Variations of platelet density (kg/l) depend mainly on cell organelle content in that high-density platelets contain more α and dense granules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000314964DOI Listing
January 2011
5 Reads

Transient visual loss triggered by scuba diving in a patient with a petrous epidermoid and combined thrombotic risk factors.

Pathophysiol Haemost Thromb 2007 17;36(6):311-4. Epub 2010 Mar 17.

Department of Ophthalmology, Medical and Health Sciences Center, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

A 25-year-old woman who developed transient neurological abnormalities after scuba diving is reported. The subsequent day she experienced transient left-side monocular blindness. Arterial ocular occlusion in apparently healthy young women is unusual, and a search for the cause of this devastating vascular event is mandatory. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/297738
Publisher Site
http://dx.doi.org/10.1159/000297738DOI Listing
August 2010
3 Reads

A biochemical study on the effect of proteolysis of beta-thromboglobulin proteins released from activated platelets on fibroblast proliferation.

Pathophysiol Haemost Thromb 2007 13;36(6):285-9. Epub 2010 Mar 13.

Thrombosis Research Unit, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India.

beta-Thromboglobulin (beta-TG) proteins are a heterogeneous group released from platelet alpha-granules on activation and have an effect on fibroblast migration and proliferation. We have previously reported the action of a metal-dependent protease on platelet-released proteins, which generates low-molecular-weight proteins that could be inhibited by ethylenediaminetetraacetic acid (EDTA). To understand the physiological significance of the breakdown of proteins after release, their effect on fibroblast proliferation in vitro was studied. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/296282
Publisher Site
http://dx.doi.org/10.1159/000296282DOI Listing
August 2010
5 Reads

Anti-heparin/PF4 complexes by ELISA in patients with disseminated intravascular coagulation.

Pathophysiol Haemost Thromb 2007 13;36(6):305-10. Epub 2010 Mar 13.

Hyogo Prefectural Awaji Hospital, Sumoto, Japan.

Heparin-induced thrombocytopenia (HIT) is known to complicate disseminated intravascular coagulation (DIC), but rarely to be complicated by DIC. We measured the titers of anti-PF4/hepatin complex antibodies by ELISA (HIT-Elisa) and examined 4 parameters of coagulation and fibrinolysis [D-dimer, thrombin/antithrombin complex (TAT), plasmin/alpha2-plasmin inhibitor complex (PIC), and antithrombin levels] in 80 patients with DIC diagnosed by a DIC scoring system. Fourteen patients were HIT-Elisa-positive, 11 of whom received heparin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000296281DOI Listing
August 2010
5 Reads

Genistein and its analogue enhanced tissue plasminogen activator activity in HeLa S3.

Pathophysiol Haemost Thromb 2007 13;36(6):298-304. Epub 2010 Mar 13.

Department of Physiological Science, Kurashiki University of Science and Arts, Kurashiki, Japan.

Soybean isoflavones of genistein and biochanin A, its analogue, promote the activity for generating tissue-plasminogen activator (tPA) from human cervical cancer cells (HeLa S3) and human umbilical vein endothelial cells (HUVEC). At a concentration of 50 microM, each of 14 types of isoflavones were added to HeLa culture solution and incubated. After 24 h, the culture solution was replaced, and then incubated for another 24 h. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000296280DOI Listing
August 2010
3 Reads

The relation between plasma tissue factor and oxidized LDL levels in acute coronary syndromes.

Pathophysiol Haemost Thromb 2007 13;36(6):290-7. Epub 2010 Mar 13.

Department of Biochemistry, Faculty of Dentistry, Marmara University, Istanbul, Turkey.

Aim: Tissue factor (TF) is a low-molecular-weight glycoprotein responsible for the initiation of the coagulation cascade. The relation between oxidized low-density lipoprotein (Ox-LDL), that has been shown to be involved in atherogenesis, and TF has not been evaluated before in circulating plasma. The aim of this study was to determine plasma levels of TF and Ox-LDL in acute coronary syndrome (ACS) and stable coronary artery disease (SCAD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000296279DOI Listing
August 2010
5 Reads

The pathophysiology of cancer and thrombosis. Summary and conclusions.

Pathophysiol Haemost Thromb 2008 27;36(3-4):212-4. Epub 2009 Jan 27.

Department of Internal Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175159DOI Listing
March 2009
3 Reads

Clinical studies with anticoagulants to improve survival in cancer patients.

Pathophysiol Haemost Thromb 2008 27;36(3-4):204-11. Epub 2009 Jan 27.

EA3499, Faculty of Medicine, University Pierre and Marie Curie (Paris VI), Paris, France.

Cancer is linked with hypercoagulability and risk of thrombosis and this close association was recognized by Armand Trousseau in 1865. The relation between cancer and blood coagulation is reciprocal: cancer induces a hypercoagulable state and predisposes to thrombosis and activation of platelets, blood coagulation and fibrinolysis interfere with tumor cell biology, tumor growth, angiogenesis and metastatic process. In the present article, we analyze the clinical trials which assessed the influence of anticoagulant treatment on the survival of patients with cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175158DOI Listing
March 2009
5 Reads

Non-anticoagulant heparins and inhibition of cancer.

Pathophysiol Haemost Thromb 2008 27;36(3-4):195-203. Epub 2009 Jan 27.

G. Ronzoni Institute for Chemical and Biochemical Research, Milan, Italy.

Low-molecular-weight heparins (LMWH) appear to prolong survival of patients with cancer. Such a beneficial effect is thought to be associated with interruption of molecular mechanisms involving the heparan sulfate (HS) chains of cell surface and extracellular matrix proteoglycans (HSPGs), growth factors and their receptors, heparanase, and selectins. The beneficial effects of heparin species could also be associated with their ability to release tissue factor pathway inhibitor from endothelium. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/175157
Publisher Site
http://dx.doi.org/10.1159/000175157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768601PMC
March 2009
5 Reads

The plasminogen activator system and cancer.

Pathophysiol Haemost Thromb 2008 27;36(3-4):184-94. Epub 2009 Jan 27.

Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

The fibrinolytic system, more appropriately referred to as the plasminogen activator system, controls not only the intravascular fibrin deposition but also participates in a wide variety of physiologic and pathologic processes. In cancer, the components of this system are involved in tumor growth, invasion and metastasis, through their effect on angiogenesis and cell migration. These components are found in most tumors and their expression signifies not only their function but also carries a prognostic value. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175156DOI Listing
March 2009
5 Reads

Microparticles and cancer.

Pathophysiol Haemost Thromb 2008 27;36(3-4):177-83. Epub 2009 Jan 27.

Department of Medicine and Program in Hemostasis and Thrombosis, Carolina Cardiovascular Biology Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.

Cancer is a prothrombotic state, with an increased prevalence of arterial and venous thromboemboli. Microparticles (MPs) are sub-micron-sized vesicles derived from activated or apoptotic cancer cells and/or host cells that may causally contribute to these clinical events, although the strength of the evidence thus far is inconclusive. We review the state-of-the-art understanding of the origin of circulating MPs, their role as a potentially important procoagulant entity in cancer, and their clinically documented association with malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175155DOI Listing
March 2009
4 Reads

Tissue factor and cancer.

Pathophysiol Haemost Thromb 2008 27;36(3-4):160-76. Epub 2009 Jan 27.

Henderson Research Centre, McMaster University, Hamilton, Ont., Canada.

Tissue factor (TF), the key regulator of haemostasis and angiogenesis, is also involved in the pathology of several diseases, including cardiovascular, inflammatory and neoplastic conditions. In the latter, TF is upregulated by cancer cells, as well as by certain host cells, and it is the interactions between these distinct pools of TF-expressing cells that likely influence tumour progression in several ways. Furthermore, the release of TF microparticles into the circulation is thought to contribute to the systemic coagulopathies commonly observed in cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175154DOI Listing
March 2009
2 Reads

Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.

Pathophysiol Haemost Thromb 2008 27;36(3-4):148-59. Epub 2009 Jan 27.

Department of Internal Medicine, Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.

Thrombosis is a leading cause of morbidity and mortality in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Several mechanisms have been proposed to cause or to contribute to the acquired thrombophilic state of these patients, including platelet and red blood cell abnormalities. The increase in white blood cell count, found in most subjects with these disorders, raises the possibility that circulating leukocytes may represent another prothrombotic factor, as demonstrated for other conditions, including sickle cell, coronary heart, and peripheral arterial diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175153DOI Listing
March 2009
3 Reads

Protease-activated receptors, apoptosis and tumor growth.

Pathophysiol Haemost Thromb 2008 27;36(3-4):137-47. Epub 2009 Jan 27.

Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Protease-activated receptors (PARs) are G-protein-coupled receptors (GPCRs) that are activated by a unique proteolytic mechanism. Besides the important role of blood coagulation factors in preventing bleeding after vascular injury, these serine proteinases actively engage target cells thereby fulfilling critical functions in cell biology. Cellular responses triggered by coagulation factor-induced PAR activation suggest that PARs play an important role in proliferation, survival and/or malignant transformation of tumor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175152DOI Listing
March 2009
4 Reads

Thrombophilia and cancer.

Pathophysiol Haemost Thromb 2008 27;36(3-4):131-6. Epub 2009 Jan 27.

Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa, Israel.

Inherited and acquired thrombophilia are well-known risk factors for venous thromboembolism. The incidence of thrombotic events in cancer patients is increased compared to normal population. Data on inherited thrombophilia and cancer is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175151DOI Listing
March 2009
2 Reads

Overview of the postulated mechanisms linking cancer and thrombosis.

Pathophysiol Haemost Thromb 2008 27;36(3-4):122-30. Epub 2009 Jan 27.

Department of Internal Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands.

Blood coagulation appears to play an important role in the occurrence of cancer and its effects may be twofold. First, in patients with cancer, blood coagulation is activated in the direction of a prothrombotic state. Second, a procoagulant environment may promote cancer in different ways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175150DOI Listing
March 2009
3 Reads

Blood coagulation and cancer: thrombosis and survival, clinical relevance and impact. An introduction.

Pathophysiol Haemost Thromb 2008 27;36(3-4):113-21. Epub 2009 Jan 27.

Department of Medical Oncology, Academic Hospital Maastricht, Maastricht, The Netherlands.

There is a strong association between deep venous thrombosis and cancer. In this review, we will discuss the increased incidence of cancer following an idiopathic venous thrombotic event (VTE) and the increased incidence of VTE and its recurrence in cancer patients. Furthermore, we will review the adverse impact VTE has on cancer patients' morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000175149DOI Listing
March 2009
2 Reads

Upper-extremity deep vein thrombosis in a patient on clozapine therapy carrying the prothrombin G20210A mutation.

Pathophysiol Haemost Thromb 2008 5;36(2):105-7. Epub 2009 Jan 5.

Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain.

Clozapine treatment for resistant schizophrenic disorders has been associated to venous thromboembolic events. We report the case of a patient who developed upper-extremity deep vein thrombosis just 2 months after starting on clozapine in whom the thrombophilia work-up revealed the presence of the prothrombin G20210A mutation. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/173731
Publisher Site
http://dx.doi.org/10.1159/000173731DOI Listing
February 2009
5 Reads

Acute complete splenic infarction in a patient with Hirschsprung's disease and literature review of complete splenic infarction.

Pathophysiol Haemost Thromb 2008 5;36(2):102-4. Epub 2009 Jan 5.

Department of Hematology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.

Here we report a case of Hirschsprung's disease presenting with acute complete splenic infarction due to thrombus in the splenic vena. MTHFR C677T (methylenetetrahydrofolate) gene homozygote mutation was a risk factor for thrombosis. According to our knowledge, this is the first report for a Hirschsprung's disease patient with acute complete splenic infarct due to isolated splenic vein thrombosis accompanied by MTHFR C677T gene homozygote mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000173730DOI Listing
February 2009
4 Reads

Therapeutic efficacy of leukocytapheresis for procoagulant microparticles during hemophagocytic syndrome.

Pathophysiol Haemost Thromb 2008 5;36(2):98-101. Epub 2009 Jan 5.

Department of Emergency and Critical Care Medicine, Kansai Medical University Hirakata Hospital, Hirakata, Japan.

Hemophagocytic syndrome (HPS) presents with signs of persistent remittent fever, hepatosplenomegaly, pancytopenia, hepatic dysfunction, and disseminated intravascular coagulation because of hypercytokinemia caused by activated T lymphocytes and macrophages. In recent years leukocytapheresis using a leukocyte removal filter (known as lymphocytapheresis, LCAP) has been applied to the treatment of various autoimmune diseases. The removal of activated monocytes during LCAP treatment appears useful for hypercytokinemia. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/173729
Publisher Site
http://dx.doi.org/10.1159/000173729DOI Listing
February 2009
7 Reads

Acute versus chronic myocardial ischemia: a differential biological profile study.

Pathophysiol Haemost Thromb 2008 5;36(2):91-7. Epub 2009 Jan 5.

Servicio Cardiología, Hospital de Basurto, Departamento de Medicina, Universidad del País Vasco UPV/EHU, Bilbao, Spain.

Objective: To determine the possible differences in lipid, thrombogenic and inflammatory marker concentrations and the presence of chronic and acute coronary artery disease (stable and unstable angina, respectively), comparing them with a group of control patients with normal coronary arteries.

Material And Methods: This prospective cohort study included 125 patients with unstable angina, 189 with stable angina and a control group of 83 patients with normal coronary arteries. Marker concentrations were measured in all 3 groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000173728DOI Listing
February 2009
8 Reads

Variation in platelet function testing has a major influence on detection of aspirin resistance in healthy subjects.

Pathophysiol Haemost Thromb 2008 5;36(2):84-90. Epub 2009 Jan 5.

Department of Vascular Diseases, University Medical Centre, Ljubljana, Slovenia.

Introduction: An increased demand for monitoring aspirin treatment by platelet function tests has been observed, but data on the biological variation of these tests are insufficient. The aim of this study was to assess the biological variation of optical platelet aggregometry and closure time in healthy subjects without aspirin and after aspirin ingestion.

Subjects And Methods: In 20 healthy subjects, blood was sampled 4 times: on 2 consecutive mornings a day after aspirin ingestion (100 mg/daily) and on 2 consecutive days of no treatment. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/173727
Publisher Site
http://dx.doi.org/10.1159/000173727DOI Listing
February 2009
7 Reads

Effect of Iron Therapy on Platelet Function among Iron-Deficient Women with Unexplained Menorrhagia.

Pathophysiol Haemost Thromb 2008 5;36(2):80-3. Epub 2009 Jan 5.

Department of Hematology, Eskisehir Osmangazi University Medical School, Eskisehir, Turkey.

This study was performed to evaluate the effect of iron therapy on platelet function among women with unexplained menorrhagia in order to better understand possible interactions between iron deficiency anemia and platelet behavior and menorrhagia. Platelet aggregation and adenosine triphosphate (ATP) release induced by 5.0 mM adenosine diphosphate (ADP), 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000173726DOI Listing
February 2009
4 Reads

Adenosine diphosphate-induced platelet aggregation correlates with platelet activation identified with the use of flow cytometry.

Pathophysiol Haemost Thromb 2008 5;36(2):75-9. Epub 2009 Jan 5.

Department of Medicine, University of Vermont College of Medicine, Colchester, VT 05446, USA.

Background: Assessment of the likelihood of platelet activation (i.e. platelet reactivity) identifies patients at high and low risk of subsequent thrombotic events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000173725DOI Listing
February 2009
4 Reads

Venous thromboembolism prevention in patients with heart failure: an often neglected issue.

Pathophysiol Haemost Thromb 2008 5;36(2):69-74. Epub 2009 Jan 5.

Dipartimento di Emergenza, Centro Emostasi e Trombosi, Medicina Interna Area Critica, Guglielmo da Saliceto Hospital, Piacenza, Italy.

Several epidemiological studies have shown a high prevalence of venous thromboembolism (VTE) complications in patients with acute heart failure; in addition, the level of risk associated with this disease is notable, ranging from 15 to 30%. Three large clinical trials have clearly demonstrated the efficacy and safety of pharmacological prophylaxis in internal medicine patients hospitalized for an acute medical disease; on the contrary, until now there are no studies which have evaluated antithrombotic prophylaxis in a selected population of patients with heart failure only. Moreover, discrepancies existing among recommendations reported in different guidelines may produce uncertainties in the management of VTE prevention in patients with heart failure and may contribute to an underuse of thromboprophylaxis in the daily clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000173724DOI Listing
February 2009
6 Reads
2 Citations

Obesity and activated protein C resistance.

Pathophysiol Haemost Thromb 2008 5;36(2):64-8. Epub 2009 Jan 5.

Endocrinology Department, Doctor Peset University Hospital, School of Medicine, Valencia University, Valencia, Spain.

It has been reported that obesity may be associated with activated protein C resistance, which could increase the thrombotic risk in these patients. The aim of our study was to evaluate this parameter in obese patients and controls, as well as the effect of weight loss on this parameter. In 63 severely or morbidly obese patients and in 65 healthy volunteers, an anthropometric and analytical evaluation (activated protein C resistance and prothrombin fragment F1 + 2) was performed at baseline and after 3 months of diet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000173723DOI Listing
February 2009
5 Reads

Major and potential prothrombotic genotypes in patients with venous thrombosis and in healthy subjects from Slovenia.

Pathophysiol Haemost Thromb 2008 5;36(2):58-63. Epub 2009 Jan 5.

Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.

The objective of our study was to investigate the prevalence of the polymorphisms factor V Leiden (FVL), prothrombin G20210A (PT G20210A), methylenetetrahydrofolate reductase C677T (MTHFR C677T), plasminogen activator inhibitor type 1 -675 4G/5G (PAI-1 4G/5G) and factor XII -4 C/T (FXII -4 C/T) in 295 Slovenian patients with venous thrombosis (VT) and 223 healthy controls in order to establish their contribution to the risk for VT. The major genetic risk factor was FVL, while PT G20210A, MTHFR 677 C/T, PAI-1 4G/5G and FXII -4 C/T polymorphisms were not. However, PT G20210A increased the risk of recurrent VT, MTHFR C677T increased the risk in older patients, while the FXII -4 T allele suggested a possible protective effect in younger patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000173722DOI Listing
February 2009
3 Reads

Successful protein C concentrate administration during initiation of oral anticoagulation in adult patients with severe congenital protein C deficiency: report of two cases.

Pathophysiol Haemost Thromb 2008 5;36(2):53-7. Epub 2009 Jan 5.

Thrombosis and Haemostasis Center, Emergency Department, Piacenza Hospital, Piacenza, Italy.

Protein C (PC) is a vitamin K-dependent proenzyme with anticoagulant activity, and patients with congenital PC deficiency are at high risk for thrombotic episodes. In patients with PC deficiency, starting treatment with oral anticoagulant drugs is associated with a transient hypercoagulable state and clinically overt thromboembolic complications before reaching a full anticoagulant effect. This report describes a successful supplementation with PC concentrate in two adult patients with moderately severe PC deficiency during the initiation of oral anticoagulation and a course of therapeutic dose of low-molecular-weight heparin for acute venous thromboembolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000173721DOI Listing
February 2009
12 Reads
2 Citations

Increased platelet cholesterol and decreased percentage volume of platelets as a secondary risk factor for coronary artery disease.

Pathophysiol Haemost Thromb 2007 6;36(1):45-51. Epub 2008 Mar 6.

Thrombosis Research Unit, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India.

Platelet hyperactivity is likely to contribute to the progression of atherogenesis and organized thrombus formation on vascular surfaces. The purpose of this study was to examine the effect of hypercholesterolemia on the cholesterol content of platelets, on platelet responsiveness and other platelet indices using platelets from 5 groups of age-matched subjects (n = 30 each), which includes healthy controls. All groups except controls had a high plasma lipid profile. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/112639
Publisher Site
http://dx.doi.org/10.1159/000112639DOI Listing
May 2008
5 Reads

Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition?

Pathophysiol Haemost Thromb 2007 6;36(1):40-4. Epub 2008 Mar 6.

Laboratoire d'Hématologie, UFR des Sciences Pharmaceutiques, Université Victor Segalen Bordeaux 2, Bordeaux, France.

Background: While aspirin is the drug most often used to prevent cardiovascular complications, its discontinuation induces an increased risk of acute coronary syndrome and ischemic stroke in some patients.

Objectives: We hypothesized that infinitesimal concentrations of aspirin could persist in plasma after its discontinuation, thereby inducing a prothrombotic effect that could be due to a modification in the mechanism of action of aspirin via the cyclooxygenase 1 (COX-1) and COX-2 pathways.

Methods And Results: We studied the effects of ultra-low-dose aspirin (ULDA) as well as those of sc-560 and ns-398, specific COX-1 and COX-2 inhibitors, on induced hemorrhagic time and in a model of laser-induced thrombosis in rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000112638DOI Listing
May 2008
9 Reads

Elevation of activated platelet-dependent chemokines and soluble cell adhesion molecules in patients with hematologic malignancies and high levels of beta-D-glucan.

Pathophysiol Haemost Thromb 2007 6;36(1):32-9. Epub 2008 Mar 6.

Division of Hematology, Kishiwada City Hospital, Kishiwada, Japan.

Most invasive fungal infections such as candidemia are frequent in patients with hematologic malignancies. We measured cytokines/chemokines (IL-6, IL-8, monocytic chemoattractant protein 1, RANTES and epithelial neutrophil-activating peptide 78), soluble molecules (sFas, sE-selectin and soluble vascular cell adhesion molecule 1) and platelet activation markers (soluble CD40 ligand, sP-selectin and platelet-derived microparticles) in patients with hematologic malignancies under prophylactic treatment with an antifungal drug (fosfluconazole). We classified patients into 2 groups by the level of beta-D-glucan. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/112637
Publisher Site
http://dx.doi.org/10.1159/000112637DOI Listing
May 2008
5 Reads

Reflectance changes in clotting native blood: evidence of a red-cell process.

Authors:
Frank A Greco

Pathophysiol Haemost Thromb 2007 6;36(1):23-31. Epub 2008 Mar 6.

The Biophysical Laboratory, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Mass 01730, USA.

When broadband light illuminates clotting native blood, the reflectance at each wavelength traces a time course with four discernible regions. Clot formation occurs just before the second phase. Two wavelengths, 471 and 771 nm, were selected for more detailed study of the first two phases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000112636DOI Listing
May 2008
5 Reads

Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behçet's disease: are they related to thrombotic events?

Pathophysiol Haemost Thromb 2007 6;36(1):18-22. Epub 2008 Mar 6.

Flow Cytometry Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain.

Behçet's disease (BD) is associated with an increased risk of venous and arterial thromboses that are associated with morbidity and mortality increase, although the mechanisms are not well established. In the present study, we used whole blood cytometry to determine the exposure of CD62 on the surface of platelets and the expression of phosphatidylserine (PS) on the surface of circulating red blood cells. Microparticle and microaggregate formation from platelets were also determined in a well-classified group of 72 patients (39 males, 33 females, aged 46. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000112635DOI Listing
May 2008
5 Reads